Last reviewed · How we verify
NCT03997292
Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China
trial testing Alteplase in Ischemic Stroke. Withdrawn.
1 September 2020
Quick facts
| Lead sponsor | General Hospital of Shenyang Military Region |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 March 2018 |
| Primary completion | 1 September 2020 |
| Estimated completion | 1 September 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
Sponsor
General Hospital of Shenyang Military Region
Who can join
18 and older, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To analyze the real situation of intravenous thrombolysis in acute ischemic stroke in China
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03997292
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Alteplase
Trials testing the same drug.
- NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
- NCT07003646 — Reperfusion Treatment in Acute Pulmonary Embolism · recruiting
- NCT07360717 — To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion · NA · completed
- NCT06621121 — A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Strok · recruiting
- NCT06194968 — Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study · recruiting
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other General Hospital of Shenyang Military Region trials
Trials by the same sponsor.
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07462546 — Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS) · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT07412249 — Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03997292 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by General Hospital of Shenyang Military Region
- Last refreshed: 25 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03997292.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing